Brain Cancer

A first-in-human clinical trial will assess the safety of a personalized vaccine to treat diffuse hemispheric glioma, an aggressive brain tumor.

Bypassing the blood-brain barrier remains an obstacle for novel therapeutics. Healio spoke to Thomas Chen, MD, PhD, founder and CEO of NeOnc, to find out how a novel nasal spray formulation to treat brain cancer overcomes these challenges.

The FDA granted accelerated approval to Ojemda for the treatment of certain children with relapsed or refractory low-grade glioma.

Focused ultrasound could provide clinicians a safer alternative in diagnosing, monitoring and treating patients with brain tumors compared with biopsy, according to findings published in npj Precision Oncology.

David J. Benjamin, MD, recently met with a patient who recalled the moment a previous physician had diagnosed him with cancer.

A Boston-area biopharma company announced positive data from a phase 1a/b trial of a novel therapeutic to treat newly diagnosed glioblastoma multiforme, resulting in the initiation of a first-line phase 2b study.

A small-molecule chemotherapeutic did not improve efficacy compared with standard therapies in adults with glioblastoma, according to the manufacturer.

An implantable microdevice designed to test treatments in patients with gliomas during standard-of-care surgery has been easily and safely incorporated into surgical practice.

The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses novel and experimental treatments for brain cancer.